TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11350703

Group type: EXPERIMENTAL
Intervention: Paroxetine (10 mg to 40 mg per day)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Problem‐Solving Treatment for Primary Care (PST‐PC)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: All treatment conditions
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Physical health component (PHC)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Minor depression (all treatments)
Number of subjects: 241
Study: 9137249

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at 20 ppm
Number of subjects: 8
Study: 8189560

Group type: EXPERIMENTAL
Intervention: Intraurethral lidocaine gel (5 or 10-minute dwell time)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plain lubricant (water-based)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-procedure anxiety
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prior experience with cystoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physician perception of pain
Number of subjects: 0
Study: 3370061

Group type: EXPERIMENTAL
Intervention: Torasemide 2.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Torasemide 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Torasemide 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Torasemide 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Torasemide (all doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study: 30931818

Group type: EXPERIMENTAL
Intervention: Use of sanitary pads at home
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Features of sanitation facilities (cleanliness, presence of a bin) at home
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Supportive policies at school (permission to use toilet when needed)
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Talking to a friend about menstruation at school
Number of subjects: 1359

Group type: EXPERIMENTAL
Intervention: Discussing menstruation with parents at home
Number of subjects: 1359
Study: 30059390

Group type: EXPERIMENTAL
Intervention: AB/HA-LLLT group (treated with low-level laser therapy)
Number of subjects: 12

Group type: COMPARATOR
Intervention: AB/HA group (not treated with low-level laser therapy)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (AB/HA and AB/HA-LLLT)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AB/HA-LLLT group
Number of subjects: 12
Study: 27993800

Group type: EXPERIMENTAL
Intervention: First-line oxaliplatin/fluorouracil (OxFU)
Number of subjects: 2530

Group type: EXPERIMENTAL
Intervention: Post-progression survival (P-PS)
Number of subjects: 2530

Group type: EXPERIMENTAL
Intervention: Second-line treatment
Number of subjects: 2530

Group type: EXPERIMENTAL
Intervention: First-line PFS and P-PS
Number of subjects: 2530
Study: 25115901

Group type: EXPERIMENTAL
Intervention: Vaniprevir 100 mg plus PR
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vaniprevir 300 mg plus PR
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vaniprevir 600 mg plus PR
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo plus PR
Number of subjects: 90
Study: 23477998

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day
Number of subjects: 785

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 785
Study: 18675477

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF) administration
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: G-CSF associated to BMSC intracoronary infusion
Number of subjects: 23

Group type: COMPARATOR
Intervention: HF control group
Number of subjects: 23
Study: 19004228

Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Ticlide
Number of subjects: 87

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control (no AD)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: AD (combined therapy)
Number of subjects: 87
Study: 15837232

Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Number of subjects: 459

Group type: COMPARATOR
Intervention: Hexavac
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 459
Study: 14635412

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study: 10421834

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) treatment in allergic asthmatic patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) treatment in COPD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group in COPD patients
Number of subjects: 0
Study: 8532785

Group type: EXPERIMENTAL
Intervention: Nutritional supplements
Number of subjects: 0
Study: 1678031

Group type: EXPERIMENTAL
Intervention: Aggregating platelets in internal mammary artery rings (contracted with noradrenaline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aggregating platelets in saphenous vein rings (contracted with noradrenaline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preincubation of platelets with aspirin (10 mumol/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thromboxane receptor antagonist SQ-30741 and serotoninergic (5HT2) receptor antagonist ketanserin
Number of subjects: 0
Study: 6581036

Group type: EXPERIMENTAL
Intervention: 8 mM diflunisal
Number of subjects: 25

Group type: COMPARATOR
Intervention: 20 mM aspirin
Number of subjects: 25

Group type: COMPARATOR
Intervention: 2 mM indomethacin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 20 mM diflunisal
Number of subjects: 25
Study: 30857261

Group type: EXPERIMENTAL
Intervention: Gamification and social incentives intervention
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 28139309

Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope (MAC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intubrite videolaryngoscope (INT)
Number of subjects: 30
Study: 27183837

Group type: EXPERIMENTAL
Intervention: Antenatal care (ANC) services in the 1st trimester
Number of subjects: 19269

Group type: EXPERIMENTAL
Intervention: Maternal age <20 years, starting ANC in the 3rd trimester, short maternal stature, being firstborn, male sex
Number of subjects: 19269

Group type: EXPERIMENTAL
Intervention: Maternal age <25 years, short maternal stature, firstborns, decreased wealth
Number of subjects: 19269

Group type: EXPERIMENTAL
Intervention: Maternal age >30 years, being firstborn, short maternal stature
Number of subjects: 19269
Study: 24360008

Group type: EXPERIMENTAL
Intervention: Aluminum chloride impregnated cord
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Displacement paste with cap
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Retraction cap with paste
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Nonimpregnated displacement cord
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Aluminum chloride impregnated cord, displacement paste, and cap
Number of subjects: 63
Study: 23040786

Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Indacaterol (150 μg and 300 μg)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study: 20026170

Group type: EXPERIMENTAL
Intervention: brief image‐based multiple behavior intervention
Number of subjects: 303

Group type: COMPARATOR
Intervention: usual care control
Number of subjects: 303
Study: 16935032

Group type: EXPERIMENTAL
Intervention: Non-aerobic training (progressive resistance training)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Aerobic training (cardio respiratory fitness)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Relaxation training (minimal impact on strength or cardio respiratory fitness)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 135
Study: 16614477

Group type: EXPERIMENTAL
Intervention: Migraine-related dizziness (MRD) subjects
Number of subjects: 15

Group type: COMPARATOR
Intervention: Migraine without dizziness subjects
Number of subjects: 15

Group type: COMPARATOR
Intervention: Headache-free controls
Number of subjects: 15
Study: 12411461

Group type: EXPERIMENTAL
Intervention: Cube-function technique
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Area-length technique
Number of subjects: 212

Group type: COMPARATOR
Intervention: 3D cardiovascular magnetic resonance technique
Number of subjects: 212
Study: 9708631

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 480 mg daily (HMA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Megestrol acetate 160 mg daily (LMA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All groups (HMA, LMA, P)
Number of subjects: 150
Study: 7617857

Group type: EXPERIMENTAL
Intervention: Continuous combined hormonal replacement therapy (HRT)
Number of subjects: 41
Study: 2213552

Group type: EXPERIMENTAL
Intervention: Sulindac, 200 mg daily for 1 week
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 505369

Group type: EXPERIMENTAL
Intervention: sulfinpyrazone
Number of subjects: 16
Study: 30253440

Group type: EXPERIMENTAL
Intervention: Women with hypermobility of the bladder neck
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Women aged >60 years with vaginal atrophy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Vaginal trophism assessed by pelvic examination
Number of subjects: 140

Group type: COMPARATOR
Intervention: Pelvic floor muscle strength across all groups
Number of subjects: 140
Study: 27941424

Group type: EXPERIMENTAL
Intervention: 200 mg of oral tedizolid phosphate once daily for 10 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 200, 300, or 400 mg of oral tedizolid phosphate once daily for 21 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: 600 mg of oral linezolid twice daily for 21 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral placebo for 21 days
Number of subjects: 100
Study: 25694201

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Anxiety disorders
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: African American race/ethnicity
Number of subjects: 302
Study: 22469418

Group type: EXPERIMENTAL
Intervention: Natural S-equol (10 mg S-equol daily for 12 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 21897773

Group type: EXPERIMENTAL
Intervention: Vestibular stimulation
Number of subjects: 198

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 198
Study: 20014253

Group type: EXPERIMENTAL
Intervention: Low-level laser treatment (635 nm, 17.5 mW, 3 times per week for 2 weeks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Low-level laser treatment
Number of subjects: 67
Study: 17023708

Group type: EXPERIMENTAL
Intervention: Diet with 40% of energy as carbohydrate
Number of subjects: 57

Group type: COMPARATOR
Intervention: Diet with 60% of energy as carbohydrate
Number of subjects: 57
Study: 14583848

Group type: EXPERIMENTAL
Intervention: L-glutamine 30 g/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 11054630

Group type: EXPERIMENTAL
Intervention: Dipyridamole (0.5 mg/kg body weight, intracoronary)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Exogenous adenosine (20 mg intracoronary)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 30
Study: 8686403

Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FAM association
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy with biochemical modulators
Number of subjects: 0
Study: 1539810

Group type: EXPERIMENTAL
Intervention: Halothane at 1.0 MAC
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.0 MAC
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Halothane at 1.5 MAC
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.5 MAC
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Halothane at 1.0 MAC (Infants)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Isoflurane at 1.0 MAC (Infants)
Number of subjects: 73
Study: 2580158

Group type: EXPERIMENTAL
Intervention: ICI 118.587 (Corwin)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31518440

Group type: EXPERIMENTAL
Intervention: CAF+CTG+i-PRF (700 rpm for 3 min)
Number of subjects: 72

Group type: COMPARATOR
Intervention: CAF+CTG
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: CAF+CTG+i-PRF
Number of subjects: 72
Study: 28453868

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training (performed on the same day or on different days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training (performed on alternating days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (maintained habitual physical activity)
Number of subjects: 0
Study: 26636423

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exenatide + L-NMMA
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 10
Study: 24424074

Group type: EXPERIMENTAL
Intervention: Pistachios (P)
Number of subjects: 20

Group type: COMPARATOR
Intervention: White bread (WB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: White bread + butter + cheese (WB+B+Ch)
Number of subjects: 20
Study: 22348319

Group type: EXPERIMENTAL
Intervention: Breath-actuated nebulizer (BAN) delivering albuterol 2.5 mg or albuterol 2.5 mg plus ipratropium 0.25 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard nebulizer delivering albuterol 2.5 mg or albuterol plus ipratropium 0.5 mg
Number of subjects: 28
Study: 20414852

Group type: EXPERIMENTAL
Intervention: Needs-Oriented Discharge Planning and Monitoring intervention, consisting of two sessions led by an intervention worker.
Number of subjects: 0
Study: 18683666

Group type: EXPERIMENTAL
Intervention: On-pump surgery (CPB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Off-pump surgery (no CPB)
Number of subjects: 40
Study: 16168737

Group type: EXPERIMENTAL
Intervention: Left medial temporal-lobe lesion patients
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal participants
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Right medial temporal-lobe lesion patients
Number of subjects: 28
Study: 15270793

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Number of subjects: 59
Study: 11382623

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% once daily
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% twice daily
Number of subjects: 596

Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 596

Group type: COMPARATOR
Intervention: Bimatoprost 0.03% once daily vs Timolol 0.5% twice daily
Number of subjects: 596
Study: 9225576

Group type: EXPERIMENTAL
Intervention: Gastrografin (100 ml administered through nasogastric tube)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Conventional management (control group)
Number of subjects: 127
Study: 8355313

Group type: EXPERIMENTAL
Intervention: Monotherapy with anti-pseudomonal third-generation cephalosporin (cefoperazone or ceftazidime)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Combination therapy with anti-pseudomonal third-generation cephalosporin (cefoperazone or ceftazidime) plus gentamicin
Number of subjects: 109
Study: 2834488

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (CY 222)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 0
Study: 28991036

Group type: EXPERIMENTAL
Intervention: β-alanine (80 mg·kg body mass·d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: β-alanine
Number of subjects: 17
Study: 25808719

Group type: EXPERIMENTAL
Intervention: Alcohol condition (BAC = 0.08)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: High arousal condition
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 97

Group type: COMPARATOR
Intervention: Juice control group
Number of subjects: 97

Group type: COMPARATOR
Intervention: Low arousal control condition
Number of subjects: 97
Study: 25037676

Group type: EXPERIMENTAL
Intervention: Impella 2.5
Number of subjects: 427

Group type: COMPARATOR
Intervention: Intra-aortic balloon pump
Number of subjects: 427
Study: 22884133

Group type: EXPERIMENTAL
Intervention: Two-stent technique
Number of subjects: 347

Group type: COMPARATOR
Intervention: One-stent group
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Patients in < 60° group
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Patients in ≥ 60° group
Number of subjects: 347
Study: 20698989

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT), treated 3 times per week for 12 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 51
Study: 18954481

Group type: EXPERIMENTAL
Intervention: Perceptual inhibition task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motor inhibition task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reaction times analysis
Number of subjects: 0
Study: 16647994

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.2 mg/kg body weight)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Rectal diazepam (0.3 mg/kg body weight)
Number of subjects: 46
Study: 12802027

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg/day for patients ≥13 years or ≥50 kg; 100 mg/day for patients <13 years or <50 kg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 10989404

Group type: EXPERIMENTAL
Intervention: Computerized reminder system
Number of subjects: 275

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 275
Study: 8781003

Group type: EXPERIMENTAL
Intervention: CQI-based intervention in 22 clinics receiving training, consultation, and networking
Number of subjects: 44

Group type: COMPARATOR
Intervention: Matched comparison clinics (control group)
Number of subjects: 44
Study: 1483156

Group type: EXPERIMENTAL
Intervention: Epinephrine injection (unconditioned stimulus) for three or four days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conditioned stimulus (CS) followed by saline injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Utrecht group experimental design
Number of subjects: 0
Study: 4018061

Group type: EXPERIMENTAL
Intervention: greater than LT (N = 11; trained at 69 watts above the workload associated with LT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: = LT (N = 12; trained at the workload associated with LT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: C (N = 10)
Number of subjects: 33
Study: 29478510

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline S100B, Tau, UCH‐L1, IL‐1β, IL‐6, IL‐8, IL‐10, IL‐13, TNF‐α, IFN‐γ levels
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Baseline Tau and day 5 BDNF levels
Number of subjects: 50
Study: 27512886

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham ESWT (Control)
Number of subjects: 40
Study: 24342419

Group type: EXPERIMENTAL
Intervention: Dual-focus 12-step group (Double Trouble in Recovery; DTR)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 203
Study: 22209649

Group type: EXPERIMENTAL
Intervention: Self-control group (participants had a choice to use or not use a balance pole)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Yoked group (received the same balance pole on the schedule used by the self-control group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Self-control group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Yoked group
Number of subjects: 28
Study: 20483164

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 61
Study: 18040883

Group type: EXPERIMENTAL
Intervention: Prevalent VFX
Number of subjects: 974

Group type: COMPARATOR
Intervention: Incident VFX
Number of subjects: 974
Study: 16187966

Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 5239

Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 5239

Group type: EXPERIMENTAL
Intervention: Rhythm control and Rate control
Number of subjects: 5239
Study: 12201397

Group type: EXPERIMENTAL
Intervention: GD2‐KLH/MPL‐A conjugate
Number of subjects: 7
Study: 10364658

Group type: EXPERIMENTAL
Intervention: Obese patients (>/=120% of ideal body weight)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Non-obese patients (<120% of ideal body weight)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Patients without vascular risk factors
Number of subjects: 325
Study: 7573730

Group type: EXPERIMENTAL
Intervention: Short nasogastric tube (NGT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Long nasointestinal tube (LT)
Number of subjects: 55
Study: 2255262

Group type: EXPERIMENTAL
Intervention: Calcium pidolate (1 g elemental calcium)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6997738

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis B vaccine
Number of subjects: 1083

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1083
Study: 31279534

Group type: COMPARATOR
Intervention: Glycine augmentation of psychotropic drug treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: D-cycloserine augmentation of psychotropic drug treatment
Number of subjects: 2
Study: 28898687

Group type: EXPERIMENTAL
Intervention: Mifepristone (200mg orally at enrollment, second dose after 24h if applicable)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 149

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Mifepristone and Expectant management
Number of subjects: 149
Study: 26498005

Group type: EXPERIMENTAL
Intervention: GV1001 telomerase peptide vaccination
Number of subjects: 33